These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 20859541)

  • 21. Improving vascular function in hypertension: potential benefits of combination therapy with amlodipine and renin-angiotensin-aldosterone system blockers.
    Siragy HM
    J Hypertens; 2010 Jan; 28(1):2-8. PubMed ID: 19797978
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of 24-h ambulatory blood pressure monitoring to assess blood pressure control: a comparison of olmesartan medoxomil and amlodipine besylate.
    Chrysant SG; Marbury TC; Silfani TN
    Blood Press Monit; 2006 Jun; 11(3):135-41. PubMed ID: 16702822
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The combination of olmesartan medoxomil and amlodipine besylate in controlling high blood pressure: COACH, a randomized, double-blind, placebo-controlled, 8-week factorial efficacy and safety study.
    Chrysant SG; Melino M; Karki S; Lee J; Heyrman R
    Clin Ther; 2008 Apr; 30(4):587-604. PubMed ID: 18498909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effect of amlodipine besylate, losartan potassium, olmesartan medoxomil, and other antihypertensives on central aortic blood pressure and biomarkers of vascular function.
    Khan BV
    Ther Adv Cardiovasc Dis; 2011 Oct; 5(5):241-73. PubMed ID: 21893558
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sustained 24-hour blockade of the renin-angiotensin system: a high dose of a long-acting blocker is as effective as a lower dose combined with an angiotensin-converting enzyme inhibitor.
    Hasler C; Nussberger J; Maillard M; Forclaz A; Brunner HR; Burnier M
    Clin Pharmacol Ther; 2005 Nov; 78(5):501-7. PubMed ID: 16321616
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antihypertensive efficacy and safety of olmesartan medoxomil compared with amlodipine for mild-to-moderate hypertension.
    Chrysant SG; Marbury TC; Robinson TD
    J Hum Hypertens; 2003 Jun; 17(6):425-32. PubMed ID: 12764406
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of amlodipine and olmesartan medoxomil in patients with hypertension: the AZOR Trial Evaluating Blood Pressure Reductions and Control (AZTEC) study.
    Punzi H; Neutel JM; Kereiakes DJ; Shojaee A; Waverczak WF; Dubiel R; Maa JF
    Ther Adv Cardiovasc Dis; 2010 Aug; 4(4):209-21. PubMed ID: 20519261
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of olmesartan/amlodipine combination therapy in patients with mild-to-severe hypertension: focus on 24-h blood pressure control.
    Parati G; Ochoa JE; Ramos C; Hoshide S; Lonati L; Bilo G
    Ther Adv Cardiovasc Dis; 2010 Oct; 4(5):301-13. PubMed ID: 20921092
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effect of an olmesartan medoxomil-based treatment algorithm on systolic blood pressure in patients with stage 1 or 2 hypertension: a randomized, double-blind, placebo-controlled study.
    Kereiakes DJ; Maa JF; Shojaee A; Dubiel R
    Am J Cardiovasc Drugs; 2010; 10(4):239-46. PubMed ID: 20653330
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rationale, design and patient baseline characteristics of OlmeSartan and calcium antagonists randomized (OSCAR) study: a study comparing the incidence of cardiovascular events between high-dose angiotensin II receptor blocker (ARB) monotherapy and combination therapy of ARB with calcium channel blocker in Japanese elderly high-risk hypertensive patients (ClinicalTrials. gov no. NCT00134160).
    Ogawa H; Kim-Mitsuyama S; Jinnouchi T; Matsui K; Arakawa K
    Hypertens Res; 2009 Jul; 32(7):575-80. PubMed ID: 19444280
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Olmesartan medoxomil-based antihypertensive therapy evaluated by ambulatory blood pressure monitoring: efficacy in high-risk patient subgroups.
    Chrysant SG; Germino FW; Neutel JM
    Am J Cardiovasc Drugs; 2012 Dec; 12(6):375-89. PubMed ID: 23116225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Monotherapy and Dual Combination Therapies Based on Olmesartan: A Comprehensive Strategy to Improve Blood Pressure Control.
    Volpe M; Santolamazza C; Mastromarino V; Coluccia R; Battistoni A; Tocci G
    High Blood Press Cardiovasc Prev; 2017 Sep; 24(3):243-253. PubMed ID: 28608026
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study.
    Punzi HA
    Ther Adv Cardiovasc Dis; 2014 Feb; 8(1):12-21. PubMed ID: 24492985
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triple combination therapy to improve blood pressure control: experience with olmesartan-amlodipine-hydrochlorothiazide therapy.
    Tocci G; Paneni F; Passerini J; Volpe M
    Expert Opin Pharmacother; 2012 Dec; 13(18):2687-97. PubMed ID: 23170911
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and tolerability of olmesartan medoxomil in patients with mild to moderate essential hypertension: the OLMEBEST Study.
    Barrios V; Boccanelli A; Ewald S; Girerd X; Heagerty A; Krzesinski JM; Lins R; Rodicio J; Stefenelli T; Woittiez A; Böhm M
    Clin Drug Investig; 2007; 27(8):545-58. PubMed ID: 17638395
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combination therapy with olmesartan medoxomil and hydrochlorothiazide: secondary analysis of the proportion of patients achieving recommended blood pressure goals from a randomized, double-blind, factorial study.
    Chrysant SG; Chavanu KJ; Xu J
    Am J Cardiovasc Drugs; 2009; 9(4):241-51. PubMed ID: 19655819
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Renoprotective effect of calcium channel blockers in combination with an angiotensin receptor blocker in elderly patients with hypertension. A randomized crossover trial between benidipine and amlodipine.
    Miyagawa K; Dohi Y; Nakazawa A; Sugiura T; Yamashita S; Sato K; Kimura G
    Clin Exp Hypertens; 2010 Jan; 32(1):1-7. PubMed ID: 20144066
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Olmesartan-based therapies: an effective way to improve blood pressure control and cardiovascular protection.
    de la Sierra A; Volpe M
    J Hypertens; 2013 Mar; 31 Suppl 1():S13-7. PubMed ID: 23389083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Subgroup analyses of an efficacy and safety study of concomitant administration of amlodipine besylate and olmesartan medoxomil: evaluation by baseline hypertension stage and prior antihypertensive medication use.
    Oparil S; Lee J; Karki S; Melino M
    J Cardiovasc Pharmacol; 2009 Nov; 54(5):427-36. PubMed ID: 19730391
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of a structured treatment algorithm on blood pressure goal rates in both stage 1 and stage 2 hypertension.
    Neutel JM; Smith DH; Silfani TN; Lee Y; Weber MA
    J Hum Hypertens; 2006 Apr; 20(4):255-62. PubMed ID: 16397514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.